Progress towards developing a vaccine for group A streptococcus based on the M protein

Internal Medicine Journal

Volumn 32, Issue 4, 2002, Pages 132-133

  Good, Michael F ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COMPLEMENT; EPITOPE; M PROTEIN; RECOMBINANT VACCINE; STREPTOCOCCUS VACCINE;

AMINO TERMINAL SEQUENCE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; BACTERIAL COLONIZATION; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CROSS REACTION; DRUG EFFICACY; DRUG RESEARCH; HUMAN; INFECTION PREVENTION; MOUTH MUCOSA; NEUTROPHIL; NONHUMAN; NOTE; PRIORITY JOURNAL; PYODERMA; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; RISK; SEROTYPE; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; TONSILLITIS; VACCINATION;

BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; HUMANS; QUEENSLAND; RESEARCH; SENSITIVITY AND SPECIFICITY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; VACCINATION;

EID: 0036965706     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1444-0903.2001.00203.x     Document Type: Note

References (8)

1. Kehoe MA. New aspects of Streptococcus pyogenes pathogenicity. Rev Red Micro 1991; 2: 147.
2. Fischetti VA. Streptococcal M protein. Sci Am 1991; 264: 58-65.
3. Hayman WA, Brandt ER, Relf WA, Cooper J, Saul A, Good MF. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol 1997; 9: 1723-33.
4. Carapetis JR, Wolff DR, Currie B. Acute rheumatic fever and rheumatic heart disease in the top end of Australian Northern Territory. Med J Aust 1996; 164: 146-9.
5. Brandt ER, Sriprakash KS, Hobb RI et al. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat Med 2000; 6: 455-9.
6. Dale JB, Chiang EY, Lederer JW. Recombinant tetravalent group A streptococcal M protein vaccine. J Immunol 1993; 151: 2188-94.
7. Dale JB, Simmons M, Chiang EC, Chiang EY. Recombinant, octavalent group A streptococcal M protein vaccine. Vaccine 1996; 14: 944-8.
8. Bessen D, Fischetti VA. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect Immun 1988; 56: 2666-72.